Premium
Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease
Author(s) -
Leurent C,
Ehlers MD
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.212
Subject(s) - clinical trial , disease , cognition , alzheimer's disease , drug development , drug trial , scalability , medicine , set (abstract data type) , data science , drug , computer science , psychiatry , database , programming language
For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, subjective, data‐poor clinical endpoints associated with neuropsychiatric disease assessment into a richer, scalable, and objective set of measurements. Incorporation of such endpoints into clinical drug trials holds promise for more quickly and efficiently developing new medicines.